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Active bioinspired materials are appealing biotechnological targets, and their study is gaining momentum.
These materials, which comprise of an inorganic matrix and one or more biomolecules, are extremely
variable and therefore may result difficult to characterize in their intimate structure. In this work we have
prepared a hydroxyapatite–L-asparaginase composite, with the perspective of using it in acute leukemia
treatment. We demonstrate that the use of electron microscopy and powder X-ray diffraction, combined
with the atomic-resolution information coming from solid-state NMR, allows us to understand the
topology of the material and how the different components interplay to obtain an active composite.
Introduction
Biological drugs (biologics1) are the fastest-growing category of
approved therapeutics, with most biologics being represented
by proteins.2 L-Asparaginases, which catalyze the hydrolysis of
L-asparagine (Asn) to L-aspartate (Asp), are one of the earliest
examples of biologics. The depletion of Asn from circulating
blood induces cell death in acute lymphoblastic leukemia
(ALL) cells, which lack the Asn-synthetase enzyme.3,4 The most
commonly used biologics in therapy are type-II bacterial
L-asparaginases (ANSII), with E. coli ANSII being in clinical use
since 1967.5 ANSII is indispensable in ALL treatment protocols
and is used for remission induction and intensification in all
pediatric and most adult regimens.6 However, treatment with
ANSII can lead to severe side effects that comprise hepato- and
pancreas toxicity, coagulation disorders and, most relevant,
allergic reactions. ANSII can be administered both intravenously
(IV) or intramuscularly (IM), the latter route being better
tolerated and less often resulting in increased hypersensitivity
reactions.7 The relevance of antibodies directed against ANSII in
children with ALL has been highlighted in the Berlin–Frankfurt–
Mu¨nster (BFM) studies, and recently reviewed:8 adverse reactions
to the enzyme mediated by either IgG or IgE antibodies, or both,
have been described.9 The appearance of antibodies increases
ANSII clearance and neutralizes the catalytic activity of the
enzyme.10 Therefore, it is of capital importance to reduce
the interaction of the enzyme with the immune system of
the patients. Several strategies have been devised to reduce
immunogenicity, the most common being PEGylation.11
However, PEG may cause severe side effects in patients with
progressive chronic kidney disease12 and can induce allergic
reactions even when administered IM.7
A radically different strategy would be to avoid contact with
the immune system of the patient altogether. Extracorporeal
processing of blood has been proposed almost forty years ago,
with limited follow-up in clinical practice, mostly because of
the limited compliance of the treatment.13 Nowadays, better-
designed biomedical devices that can be used to physically
confine active components within a membrane are available.
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This possibility mitigates the need of obtaining an enzyme that
is able to evade immune recognition. On the other hand, the
incorporation of an enzyme within a device requires that the
formulation has a long lifetime, both on the shelf and in operando,
that it is easily handled (weighted, transferred, etc.) and that the
active site is accessible. For these reasons, the possibility of
extracorporeal processing has triggered a strong interest in the
protein immobilization community.14,15
Here, we describe the design of a biomaterial that carries an
ANSII chimera attached to a hydroxyapatite (HA) support, because
HA-based composites have already been used as new biomedical
devices,16–18 drugs and vaccine carriers,19–24 and because immobili-
zation of enzymes often results in stabilization.25
The characterization of bioinspired materials is a complex
accomplishment because it needs to rely upon the character-
ization of both the inorganic matrix and the biomolecular
component.26–31 In this context, NMR plays a very important
role, as it is the only methodology that can access atomic-level
information on both components.32–41
Results and discussion
Native, therapeutically active ANSII is a homotetrameric assembly
of about 140 kDa with D2 symmetry (a dimer of two intimate
dimers)42 with four catalytic sites per tetramer. We have previously
provided the NMR characterization of ANSII in its free, PEGylated,43
sugar-conjugated forms44 and bound to gold nanoparticles.45 We
fused ANSII with a C-terminal tail encompassing the HA-promoting
peptide (HABP) W6p (RWRLEGTDDKEEPESQRRIGRFG; Fig. S1,
ESI†).46 Gel-electrophoresis and dynamic light scattering show that
ANSII–HABP is smaller (B80 kDa) than the native enzyme, and
likely corresponds to a single intimate dimer (Fig. S2–S4, ESI†).
However, it still retains about one-fourth of the catalytic activity per
monomer (Fig. S5, ESI†).
The HA/ANSII–HABP composite was prepared by self-promoted
biomimetic mineralization of HA driven by HABP (see ESI†). After
repeated washings to remove the unbound enzyme, the activity of
HA/ANSII–HABP was assayed using NMR (Fig. S6 and S7, ESI†),
under the same conditions used for metabolomic profiling of serum
(Fig. S7, ESI†).47 HA/ANSII–HABP was still active after more than
three months of storage at 4 1C. The efficacy of HA/ANSII–HABP was
then tested in vitro on human ALL cells (697 cell line), and compared
to either the wild-type (WT) enzyme or the commercial product
Oncaspar (i.e. PEG-ANSII). All ANSII preparations were added at
0.74 U mL1 concentration, according to previous reports.48,49
HA/ANSII–HABP was kept separated from leukemic cells via a
3.5 kDa cut-off dialysis membrane. HA/ANSII–HABP reduced the
leukemic cell viability to the same extent (after 24 hours of
incubation) and evenmore (at 48 hours of incubation) compared
to either the free enzyme or the commercial product (Fig. 1).
HA/ANSII–HABP was further characterized using powder
X-ray diffraction (XRD), scanning electron microscopy and solid-
state NMR. The XRD profile (Fig. 2), shows the typical diffraction
pattern of HA,50 while the diffraction at low 2y suggests the
simultaneous presence of some octacalcium phosphate (OCP).51
The diffraction peaks are broad, as expected for crystallites
of small size. By elemental analysis, the protein content was
found to be on the order of 40  1% in the dried material.
Fig. 1 Effects of different ANSII preparations on the proliferation of ALL cells.
ALL 697 cells were treatedwith different ANSII preparations (HA/ANSII–HABP,
WT ANSII and Oncaspar) at a concentration of 0.74 U mL1 for 24 and
48 hours and the number of live cells, determined via the Trypan Blue
exclusion test, was measured. HA/ANSII–HABP was confined in a device
with walls consisting of a 3.5 kDa cut-off dialysis membrane. Data are
mean values standard error of the mean of three independent experiments.
48 hours: HA/ANSII–HABP vs. WT ANSII, p = 0.00116; HA/ANSII–HABP vs.
Oncaspar, p = 0.00449, as tested by one way ANOVA.
Fig. 2 Top: XRD profile of the HA/ANSII–HABP composite (black line).
Bottom: Calculated XRD diffractogram of hydroxyapatite (red) and octa-
calcium phosphate (blue) shown as stick plots.
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SEM micrographs show that the material is composed of
fused structures, homogeneous in shape and size (Fig. 3),
which more closely resemble HA nanosheets,52 rather than
OCP spherical particles.
Combustion elemental analysis provided the elemental
composition and a quantitative determination of the protein
content, found to be of the order of 40% in the dried material.
After reacting 1 mL of the mixture, and rinsing it several times,
about 28 mg of wet material are obtained. From the content of
the reaction mixture (see ESI†), the theoretical yield of the dry
material can be calculated: assuming that only HA will form, with a
40% w/w protein content in the material, 4 mg of the composite
should precipitate. If, on the contrary, only OCP is formed, about
2mg of the composite should precipitate. Thus, in the wetmaterial,
we can estimate that 6.5–13% will consist of HA/ANSII–HABP.
HA/ANSII–HABP was further characterized in terms of their
elemental composition using energy dispersive X-ray spectro-
scopy (EDS). Inductively coupled plasma (ICP) emission
was additionally used for elemental analysis of the total Ca
and P content in the sample (Table 1). The ICP measurement
shows a Ca/P ratio of 1.78, higher than the theoretical HA value
of 1.67 (Tables 1 and 2). Such a phosphate depletion has been
also observed53 for HA prepared in the presence of a mineral
binding peptide, and is possibly due to a disordered phase in
addition to the ordered HA phase.53
In order to fully understand the activity of the material, it is
necessary to link the bulk observations to the molecular scale,
answering the following questions:
(a) are the ordered and the disordered layers in contact with
each other?
(b) is the protein in contact with the ordered phase, with the
disordered one or with both?
(c) is the protein exposed to the solvent, thus accessible to
the substrate?
We here demonstrate how solid-state NMR is the methodology
of choice to answer these questions.
A Bloch decay (BD), a homonuclear decoupled 1H spectrum
of HA/ANSII–HABP and a BD spectrum of HA are shown in
Fig. 4. The presence of the HA phase is confirmed by the BD
spectrum (red), where HA/ANSII–HABP has the same OH
resonance at 0.2 ppm as synthetic HA (green). The BD spectrum
shows a broad intense water resonance at 5.3 ppm (consistent
with the high water content in HA/ANSII–HABP); however, as will
be shown, these water molecules are not necessarily residing at
the enzyme–mineral interface. The peak at 1.3 ppm is associated
with the aliphatic side-chain protons of the protein chimera but
may include some contribution from HA as can be seen by
comparing with the mineral spectrum. In the homonuclear
decoupled wPMLG spectrum (violet) of HA/ANSII–HABP, the
water line is extensively attenuated, exposing three clear bands
at 1.3 ppm, 4.5 ppm and 7.2 ppm from ANSII–HABP protons.
Although the wPMLG experiment is intended to enhance
resolution by 1H–1H decoupling, in this biomaterial sample we
find that it improves the capability to observe the protein
proton lines via a simple solvent suppression mechanism.
Exposing the protons to a strong effective field tilted at the
magic angle causes exclusive broadening of the water signal
beyond detection due to coincidental matching of the water
motional time scale with the field’s decoupling cycle period
(15 ms). The motions experienced by ANSII–HABP are quite
different and therefore are not affected similarly by the homo-
nuclear decoupling. The widths of the ANSII–HABP proton
lines are 3–6 ppm and they result from immobile protein
molecules: these lines are collectively associated with ANSII–
HABP protons belonging to side-chains, Ha and amide protons.
The peak at 1.3 ppm may mask a smaller contribution from HA
(see the spectrum of synthetic HA).
The deconvolution54 of 1H–31P cross-polarization (CP)53
spectra of HA/ANSII–HABP obtained under MAS (Fig. 5a and
Fig. S8, ESI†) reveals two phosphate species, as synthetic HA,53
that can be attributed to two different layers. The peak at
2.9 ppm (FWHM 1.2 ppm) is typical of the phosphate resonance
in HA crystals (denoted hereafter as PHA) while the peak at
Fig. 3 SEM images of the HA/ANSII–HABP composite, taken with (upper
panels) and without (lower panels) conductive staining, revealing a highly
porous structure, which is most suitable for maintaining the accessibility of
the enzyme. The high protein loading at the surface reduces the achiev-
able resolution.
Table 1 Secondary electron emission analysis of HA/ANSII-HABP
Element Average wt% Std% Average atom count Std
C 23 3 1.9 0.2
N 10 3 0.7 0.2
Ca 26 4 0.7 0.1
P 14 2 0.44 0.06
Table 2 Summary of the elemental composition of HA/ANSII–HABP,
compared with expected values
Ratio Measured – EDS Measured – ICP
Expected
for HA
Expected
for OCP
Ca/P 1.6  0.3 1.78 1.67 1.33
Ratio Measured Expected for current protein chimeric construct
C/N 2.8  0.9 3.57
Protein% 47  7
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2.6 ppm (FWHM 3 ppm) is attributed to hydrogen phosphate
ions (HPO4
2) (denoted hereafter as PHP) which are part of the
disordered calcium phosphate phase that resides at the HA/
ANSII–HABP interface55 (this peak cannot be attributed to beta-
glycerophosphate because it exhibits a higher chemical shift56).
Mono-acid phosphates were shown to adopt a large range of
chemical shifts, depending on the surroundings ions. In HA/
ANSII–HABP this is reflected in the significant width, 7 ppm
(FWHM), of the PHP peak.
55
To characterize the proximity of interfacial and bulk protons
and phosphates, 31P CP build-up curves were analyzed.53
31P CP build-up measurements were carried out by varying
the contact time from 100 ms to 10 ms, and the intensities of
the PHA (black) and PS (red) peaks were plotted against the
contact time (see Fig. 5b). Recently, similar magnetization
build-up curves were used to isolate magnetization transfers
between interfacial protons and phosphates and bulk protons
and phosphates in apatite samples prepared with a bone
protein binding peptide which displays similar properties of
having a crystalline phase of HA and a disordered phase
containing calcium phosphate ions and the biomolecule.53
Here, we follow a similar strategy.
These intensity buildup curves show the rate of magnetiza-
tion transfer from adjacent protons to the two phosphate
species. The relative line intensity in Table 3 is derived from
the fit to the experimental phosphate line, in Fig. 5 as described
below. The integral (integrated intensity) of the experimental
phosphate peak for each contact time point was calculated and
the values were normalized to the highest integral to obtain the
buildup normalized to 1. Each spectrum was then deconvolved
into the two phosphate contributions and the calculated area
under each deconvolved peak was taken as a fraction of one.
Therefore, the intensity per phosphate peak and per contact
point was overall normalized to the fractional intensity of that
phosphate species within each contact time spectrum and
to the intensity of the highest signal in the CP buildup curve.
The curve of PHA was fitted using eqn (1) and that of PHP was
fitted using the extended eqn (2) which accounts for relaxation
processes which further influence transfer.
IðtÞ ¼ I0  1 e
 ttCP
 " #
(1)
IðtÞ ¼ I0
1 tCP
TH1r
 ! e  tTH1r
 
 e 
t
tCP
 264
3
75 (2)
In these equations, I0 is the overall intensity of phosphate
magnetization, tcp is the typical CP time and (T
H
1r) is the
longitudinal rotating frame relaxation time of the protons.
The kinetic parameters, summarized in Table 1, were
deduced from best-fitted curves calculated by minimizing the
deviations of signal intensity I0, the magnetization transfer
time constant (tcp) and the
1H rotating frame relaxation time
(TH1r) in calculations and in experiments.
The relatively low normalized PHA intensity, 0.27, is indica-
tive of the low content of crystalline HA in ANSII–HABP. This
line typically has an intensity 40.6 in other co-precipitation
procedures of proteins with HA.53 The extracted magnetization
transfer time of PHA, 3.1 ms (Table 3), closely resembles the
value for synthetic HA (see Fig. 6),53 and is somewhat inter-
mediate between hydroxyl-to-phosphate transfer time in apatite
crystals grown with an osteonectin binding peptide and inter-
facial transfer time from protons outside the crystals to crystal-
line phosphates in that same sample.53
This finding suggests that either water or protein molecules
are located close to the faces of the HA crystal and transfer
magnetization to ordered (crystalline) phosphate ions in
exposed crystal surfaces. The transfer rate of the PHP line,
0.5 ms, is similar to the magnetization transfer observed for
interfacial phosphates in the aforementioned apatite grown
with an osteonectin binding peptide.
Fig. 4 1H NMR spectra of ANSII–HABP acquired using wPMLG for
homonuclear-decoupling (violet) and a simple 901-acquisition (i.e. a Bloch
decay) (red). A 1H Bloch decay spectrum (green) of synthetic hydroxy-
apatite prepared without calcination is also shown for comparison.
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To further probe the local environment sensed by phosphate
groups and identify their distribution within the sample,
we recorded two-dimensional 1H–31P HETCOR MAS NMR
spectra (Fig. 7).
During the 1H magnetization evolution under the chemical
shift in t1, the PMLG decoupling sequence was used to suppress
1H–1H dipolar couplings. Fig. 7 shows an intense cross peak
between HA hydroxyl protons at 0.2 ppm and phosphates at
2.9 ppm (i.e. PHA). It also shows a group of narrower cross peaks
correlating 1H at 1.3 ppm, 4.0–6.5 and 7.0–8.5 ppm along F1
with PHP phosphates. These resonances are attributed to the
protein protons that transfer magnetization to proximal PHP
phosphates in the mineral. The homonuclear decoupling
employed in t1 effectively removes water proton excitation,
and therefore no correlations are observed between water and
phosphate species. This is quite different from other preparations
of apatite minerals,53,57 whereby a strong correlation of water
protons with phosphates in a disordered calcium phosphate layer
on HA crystallites was observed. The absence of the water reso-
nance in the 2D HETCOR spectra is further demonstrated in the
1H projections (taken along the phosphate maximal intensity) of
Fig. 5 (a) An example of the 31P CP spectrum of HA/ANSII–HABP obtained using 3.6 ms contact time deconvoluted using the DMFIT program. The
experimental spectrum (blue) is shown with the sum of simulated peaks (red) and individual lines at 2.6 ppm (green) and 2.9 ppm (purple). (b) 31P intensity
buildup with increasing CP contact time of PHA phosphates (black) and PHP phosphates (red).
Table 3 Kinetic parameters of 31P magnetization buildup of phosphates in
HA/ANSII–HABP
Peak position
(ppm) Assignment
Width
(ppm) tcp (ms) T1r (ms)
Normalized
intensity
2.9 PHA 1.4 3.1 — 0.27
2.6 PHP 5.0 0.5 13.1 0.73
Fig. 6 31P CP buildup curves of PHA (black) and of the HA phosphate line
in hydroxyapatite prepared via a titration method at 310 K (green53). It
shows that the rate of magnetization buildup of PHA in ANSII–HABP is
similar to that of HA, suggesting that this line represents a 31P nucleus in a
crystalline environment.
Fig. 7 1H–31P heteronuclear correlation (HETCOR) spectra of HA/ANSII–
HABP using contact times of 0.5 ms.
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these measurements as compared to similar measurements in
synthetic HA where the relative intensity is much different
(see Fig. S9, ESI†). Similar 1H–31P 2D HETCOR measurements
without PMLG decoupling did not show any water cross peaks
with phosphates, so it is apparent that water molecules are
distantly located from phosphates.
In summary, these spectra show that the protein resonances
correlate with PHP in the disordered layer, which in turn is
connected with the PHA phase. The latter crystalline phase is
mostly excluded from water, suggesting also that this bulk
mineral phase is overall distant from the biomolecule. From
these data, we can conclude that ANSII–HABP is interacting
with a layer of interfacial phosphates (PHP), probably of the
mono-acid type, and has no direct interactions with HA crystal-
lites. Finally, no correlations are here observed between water
and phosphate species: this means that the water molecules are
either located far from the phosphates or are too dynamic to be
detected in dipolar-based magnetization transfer experiments.
The 1H–13C CP58,59 MAS spectrum with ramped 1H amplitude
(ramp-CP60) has low intensity and resolution (Fig. 8, middle
trace) that are both increased when ramp-CP is hybridized with
the nuclear Overhauser effect (NOE, Fig. 8, top trace):61 this
sequence results in the appearance of a larger number of
signals. Most of these additional peaks appear in the aliphatic
region (0–75 ppm) and some peaks from aromatic side chains
also appear (110–140 ppm). Moreover, some new peaks can be
observed also in the carbonyl region (150–180 ppm). The
observed peaks around 153 ppm belong to Cz of the arginine
side-chains, while those around 178 ppm relate to Cg or Cd of
the aspartate and asparagine or glutamate and glutamine side-
chains, respectively (Fig. S10, ESI†). These observations suggest
that the additional peaks, observed via NOE, originate from
those chemical groups or amino acid residues that undergo
significant motion on the milliseconds (or faster) timescale,
and are therefore not detectable by the dipolar-coupling based
CP. One needs to consider the hypothesis of a substantial
water–protein magnetization transfer (either through intermo-
lecular NOE, which is prevailing at high spinning rates and low
temperature, or through chemical exchange followed by spin
diffusion, which is most probably dominant under the present
experimental conditions62) at the time of the NOE mixing, plus
the contribution due to direct 13C excitations which is intrinsic
for the pulse sequence applied.61 Either of the two mechanisms
does not detract from the idea, but rather corroborates it, that a
large share of the protein is sizably exposed to water.
The topology of HA/ANSII–HABP (Fig. 9) that can be derived
from our integrated analysis is summarized below.
(a) The microscopic characterization demonstrates that the
material is composed of small lamellar structures that closely
resemble hydroxyapatite, and PXRD confirms this conclusion.
(b) The secondary electron analysis shows that there is
a phosphate depletion, consistent with previous reports on
HA/peptide composites.
(c) Solid-state NMR investigation of the inorganic part shows
that the ordered HA phase is not in contact with the protein
and the disordered layer is in intimate contact with the protein.
This further shows that the two inorganic phases are in contact
with each other, and water is closer to the protein and largely
excluded from the mineral phases.
(d) Protein solid-state NMR indicates that the enzyme is not
completely immobile in the material, but undergoes extensive
motions (Fig. S10, ESI†), suggesting that it is mainly sitting
at the surface of the particles, rather than being entrapped
within the material (Fig. 9). Despite the preserved mobility, the
observed chimeric ANSII–HABP is stably linked to the mineral
particles, as discussed above.
(e) The tests against the cells and those in vitro confirm that
the protein is stable in the construct for several months and
demonstrate that the material is active.
Fig. 8 13C NMR spectra of HA/ANSII–HABP (black) and PEGylated
wtANSII43 (red) obtained under MAS using CP only (middle and bottom
spectra) or CP–NOE (topmost). The spinning sidebands are marked as ‘*’.
NOE mixing was set to 1.3 s and the CP contact time was 1.2 ms.
Fig. 9 Scheme of the arrangement of the components of HA/ANSII–
HABP.
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Nowadays ANSII is still indispensable6 in the treatment of
ALL patients and new ANSII preparations are needed to over-
come the limitations of the current ANSII therapy, especially
immunogenicity. The results obtained in an in vitro assay on
human leukemic cells with HA/ANSII–HABP, and the protocols
for its characterization, provide new perspectives for the devel-
opment of microreactors to be used as possible innovative
biomedical devices able (i) to increase the stability of ANSII,
(ii) to extend Asn depletion in the serum and at the same time
(iii) virtually to reduce immunogenicity. Collectively, our results
show that enzymes processing small substrates can be effi-
ciently and profitably bound to the surface of a HA matrix by
engineering the wild-type construct with HA promoting
peptides.
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